Hillhouse-Backed Biotech Firm I-Mab Eyes $100M In US IPO

I-Mab Biopharma, a Chinese-clinical stage biopharmaceutical company, has filed for an up to US$100 million IPO of American Depository Shares (ADS) on the Nasdaq on Tuesday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in